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Abstract: Peroxisome proliferator-activated receptor (PPAR) agonists are used as adjunct therapy in the treatment of 
diabetes mellitus. Fibrates, including fenofibrate, gemfibrozil, benzafibrate, ciprofibrate, and clofibrate act on PPAR alpha 
to reduce the level of hypertriglyceridemia. However, agonists (ligands) of PPAR-beta/delta receptors, such as tesaglita-
zar, muraglitazar, ragaglitazar, imiglitazar, aleglitazar, alter the body's energy substrate preference from glucose to lipids 
and hence contribute to the reduction of blood glucose level. Glitazones or thiazolidinediones on the other hand, bind to 
PPAR-gamma receptors located in the nuclei of cells. Activation of PPAR-gamma receptors leads to a decrease in insulin 
resistance and modification of adipocyte metabolism. They reduce hyperlipidaemia by increasing the level of ATP-
binding cassette A1, which modifies extra-hepatic cholesterol into HDL. Dual or pan PPAR ligands stimulate two or more 
isoforms of PPAR and thereby reduce insulin resistance and prevent short- and long-term complications of diabetes in-
cluding micro-and macroangiopathy and atherosclerosis, which are caused by deposition of cholesterol. This review ex-
amines the chemical structure, actions, side effects and future prospects of dual and pan PPAR agonists. 
Keywords: Diabetes mellitus, PPAR agonists, thiazolidinediones, fibrates, medicinal chemistry. 
INTRODUCTION 
  Diabetes mellitus is a common metabolic disease affect-
ing millions of people worldwide. Type 1 diabetes is usually 
caused by immune destruction of pancreatic islet cells while 
type 2 is associated with insulin resistance, hyperglycemia 
and other metabolic conditions such as hypertension, obesity 
and hyperlipidemia. 
  Thiazolidinediones and fibrate drugs are one of the most 
commonly used medications in the treatment of type 2 diabe-
tes, hyperlipidemia and insulin resistance. How do these 
drugs work? They bind to peroxisome proliferator-activated 
receptors (PPARs) which are located in cell nuclei and be-
have as transcription factors regulating the expression of 
several genes [1]. Activated PPARs play important roles in 
the regulation of cellular development and differentiation, 
and the metabolism of body fuel including carbohydrates, 
lipids and proteins [2,3]. PPARs increase the proliferation of 
peroxisomes in the hepatic cells of frogs [4]. They also bind 
to special regions of DNA of certain genes and are able to 
heterodimerize when in contact with retinoid X receptor. The 
biological effects of PPARs depend on the shape of their 
ligand-binding domain, which is modified by ligand binding 
protein and by scores of other co-activator and co-repressor 
polypeptides [5]. PPARs may bind to several endogenous   
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ligands, including free fatty acids, eicosanoids, 
prostaglandins and leukotrienes [6].  
TYPES OF PEROXISOME PROLIFERATOR-
ACTIVATED RECEPTORS (PPARs) 
  Alpha, beta, gamma and delta PPARs have been identi-
fied [7]. The alpha isoform is widely expressed in the liver, 
kidney, cardiac, skeletal muscle and adipocytes. In contrast, 
the beta/delta type is mostly observed in the brain, adipose 
tissue, and the skin. PPAR is found in the intestinal mucosa, 
adipocytes and kidney [8]. PPAR, which was identified in 
humans in 1992, has a similar structure to PPAR. The name 
PPAR is widely used in the US, whereas the use of PPAR 
is more widespread in Europe [9].  
 PPAR is located in chromosome 22q12-13.1; PPAR/ 
in chromosome 6p21.2-21.1 and PPAR in chromosome 
3p25. Mutation in any of the following areas has been attrib-
uted to various abnormalities of the metabolic syndrome [10, 
11]. 
PPAR-alpha Receptors  
 PPAR receptor was the first set of PPARs discovered. It 
was shown that in addition to its ability to increase 
peroxisomal numbers in rodent liver tissue, it does improve 
insulin sensitivity [4]. The main ligands of PPAR receptor 
are fibrate drugs (fenofibrate, gemfibrozil, benzafibrate (9), 
ciprofibrate, and clofibrate), which were originally used as 
an adjunct therapy in the treatment of hypercholesterolemia. 
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mia. This is achieved by facilitating the degradation of very 
low density lipoprotein (VLDL) and reduction in its produc-
tion. Activation of lipoprotein lipase will result in the re-
moval of triglycerides from VLDL. In addition, lipid reduc-
tion is achieved by stimulation of intracellular fatty acid oxi-
dation and utilization [12]. A more recent report shows that 
reduction in these parameters lead to a decrease in cardio-
vascular events [13].  
PPAR-delta Receptors 
  The function of PPAR-delta has been the target of many 
studies in recent years because it was shown that stimulation 
of PPAR-delta modifies the body's energy fuel preference 
from glucose to fat. The structure of PPAR is almost the 
same as that of PPAR [14].  
PPAR-gamma Receptors 
 PPAR receptor is the main target of thiazolidinediones 
(TZDs), medications used in the treatment of type 2 diabetes. 
Other ligands that stimulate PPAR receptors include 
NSAIDs such as ibuprofen and indoles. Ligands that stimu-
late PPAR receptors are used in the treatment of 
atherosclerosis induced by hyperlipidaemia because stimula-
tion of these receptors increase the expression of ABCA1, 
which modifies extra-hepatic cholesterol into HDL. This 
results in a net decrease in the amount of circulating lipids 
and lower deposition of lipids in the wall of blood vessels. 
Three forms of PPAR receptors have been identified. These 
include PPAR1 receptor, which is expressed in many tissues 
including heart, muscle, colon, kidney, pancreas, and spleen; 
PPAR2 receptor found mainly in adipocytes, and PPAR3 
receptor expressed predominantly in macrophages, large 
intestine and white adipose tissue [2]. 
DUAL PPAR MODULATORS 
  A fourth class of PPAR agonists, called dual or pan 
PPAR ligands, bind two or more PPAR isoforms. This class 
of PPAR modulators is currently under intensive investiga-
tion for the treatment of diabetes mellitus and its complica-
tions [15, 16]. Many dual-pan PPAR modulators have been 
identified. The best known of these compounds include 
tesaglitazar (1), muraglitazar (2), naveglitazar (3), ragaglita-
zar (4); farglitazar (5), imiglitazar (6); aleglitazar (7), and 
netoglitazone (Table 1)  
STRUCTURE OF DUAL/PAN PPAR MODULATORS 
(LIGANDS) 
  PPARs have modular structure with 5 functional domains 
including an N-terminal region; DNA-binding domain; 
flexible hinge region; ligand binding domain (LBD) with a 
large secondary structure containing 13 alpha and a beta 
helices. LBD is the site at which the receptor is activated or 
inhibited. The fifth domain is the C-terminal [17]. Most of 
the well known dual PPAR modulators including 
muraglitazar, tesaglitazar and aleglitazar have two methyl 
groups  each. They also have hydroxyl groups (Tables 1,  
2, 3). 
ACTIONS OF DUAL/PAN PPAR MODULATORS 
  The action of dual/pan PPAR modulators is based on the 
combined action of PPAR-alpha, PPAR delta/beta and/or 
beta gamma agonists, a quassi non-selective activation of 
PPAR. The main agonists of PPAR-alpha are fibrate drugs 
(fenofibrate,  gemfibrozil, benzafibrate (9), clofibrate and 
ciprofibrate,) which belong to the class of amphipathic car-
boxylic acids. They reduce the plasma level of triglycerides 
and cholesterol, thus reducing atherosclerosis and other 
lipid-induced complications. On the other hand, PPAR- 
beta/delta modulators, change the body's energy source from 
glucose to lipids [14], thereby depleting tissue lipids, which 
will reduce the risks arising from hyperlipidemia. PPAR-
gamma modulators, such as thiazolidinediones help to re-
duce insulin resistance, hypercholesterolemia and therefore 
contribute to the reduction of late vascular complications of 
diabetes mellitus (Tables 1, 2, 3).  
 Muraglitazar  (2) has been shown to reduce HbA1C and 
improve lipid profile in patients with diabetic mellitus [18]. 
In spite of the clinical efficacy of muraglitazar (2), phase III 
clinical study with muraglitazar (2) was completely abol-
ished because it was associated with oedema and heart fail-
ure [19]. However, studies in db/db mice have shown that 
muraglitazar (2) can prevent the onset of diabetes mellitus 
and its complications [20]. 
  Another prospective dual PPAR modulator, tesaglitazar 
(1), was reported to be able to reduce the degree of athero-
sclerosis in mice with LDL receptor deficiency [21] and 
suppress both hyperglycemia and dyslipidemia [22]. Further 
trials on the use of tesaglitazar (1) have since been halted 
because it induces kidney failure. However, in contrast to 
previous studies, new reports showed that tesaglitazar (1), 
can indeed improve metabolic abnormalities and renal func-
tion, decreased blood pressure, and prevent glomerular and 
interstitial lesion in obese Zucker rats [23] and db/db mice 
[24]. 
 Chiglitazar  (10) is a relatively new PPAR alpha/gamma 
dual agonist, which has been shown to improve impaired 
insulin and glucose tolerance in monosodium glutamate 
(MSG)-obese rats. It enhances insulin sensitivity index and 
reduce the HOMA (Homeostatic Model Assessment) 
index. In addition, administration of chiglitazar (10) reduces 
alanine gluconeogenesis and hepatic glycogen levels in MSG 
obese rats. Chiglitazar (10) decreases plasma triglyceride, 
total cholesterol, non-esterified fatty acids and low density 
lipoprotein-cholesterol levels in animal models of diabetes 
[25] (Tables 4, 5). 
SIDE EFFECTS OF DUAL/PAN PPAR MODULA-
TORS 
  Investigators working on the development of dual/pan 
PPAR modulators have encountered many failures with 
many of the agents they have developed. Benzafibrate (9) 
stimulates all of the three PPARs with the same efficacy. It is 
the first and still the only pan-PPAR agonist used therapeuti-
cally. Benzafibrate (9) increases HDL-C level and lower 
blood triglyceride and glucose levels. It enhances insulin 
sensitivity. The use and testing of many dual/pan PPAR 
modulators have been discontinued because of severe side 
effects including renal failure, fibrosarcomas, urinary cancer 
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Table  1.  Name, Chemical Structure of Selected Dual (/) PPAR Modulators 
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Table 2.  Dual PPAR Agonists (Ligands) and their Main Actions 
Dual PPAR Modulators  Indication  Dosage  Effect  Remarks 
1.  PPAR / 
Tesaglitazar 
(1) 
Hyperlipidemia  0.5 mg/day  reduces plasma triglycerides, 
increases HDL-C, stimulates 
fatty acid uptake and utilization 
in muscle cells and hepatocytes, 
reduces organ steatosis 
Discontinued by AstraZeneca on 
May 26, 2006 
Muraglitazar 
(2) 
  5 mg/day    Discontinued by Bristol-Myers 
Squibb on May 18, 2006 
Ragaglitazar 
(4) 
  1 mg/day  Discontinued by Novo Nordisk 
in 2006 
 
Imiglitazar 
(6) 
    Suspended by Takeda Pharma-
ceutical in December 20, 2004 
 
Aleglitazar 
(7) 
Type 2 diabetes melli-
tus 
Phase II     
2.  PPAR / 
Compound T913659  Hyperlipidemia    Under development by Tularik   
3.  PPAR / 
Propionic acid derivative 
(8) 
Type 2 diabetes mellitus, 
hyperlipidemia 
  New compound developed by 
Eli Lilly 
 
 
Table 3.  Name, Chemical Structure of Selected Dual (/) PPAR Modulators (Ligands) 
Compound Chemical  Structure 
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Table 4.  Name, Chemical Structure of Selected Pan (//) PPAR Modulators (Ligands) 
Compound Chemical  Structure 
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Table 5.  Pan PPAR Agonists (Ligands) and their Main Actions 
Pan PPAR modulators  Indication  Dosage  Effect  Remarks 
Benzafibrate (9)  Type 2 diabetes mellitus, hyperlipide-
mia, atherosclerosis 
  increases HDL-C 
level, lowers blood 
triglyceride and glu-
cose levels, enhances 
insulin sensitivity. 
 
Marketed by Boehringer 
Mannheim 
GmgH/Chong Kun Dang 
Pharma 
Chiglitazar 
(10) 
Type 2 diabetes mellitus      Currently in Phase II by 
Shenzhen Chipscreen Bio-
sciences 
Netoglitazone Obesity      In phase II. Introduced by 
Mitsubishi Pharma/Perlegen 
Sciences 
 
Table 6.  Side Effects of Dual/Pan PPAR Agonists (Ligands) 
Dual/pan PPAR Modulators  Side Effect  Cause of Side Effects  Remarks 
1. Dual (PPAR /)  
Tesaglitazar  
(1) 
Anaemia, leucopenia, renal failure, 
fibrosarcomas,  
Stimulation of DNA synthesis [24]  Discontinued in 2006 
Muraglitazar 
(2) 
Heart failure, myocardial infarction 
and stroke 
Blocks calcium channel [13]  Discontinued in 2006 
Ragaglitazar 
(4) 
Anaemia, oedema, and urinary tract 
cancer in rodents 
Causes overexpresssion of early growth 
response-1 (EGr-1), phosphorylation of c-
Jun and ribosomal S protein [25, 26] 
Discontinued in 2006 
Imiglitazar 
(6) 
Liver dysfunction  Effect of cytochrome p450?  Suspended in 2004 
2. Pan PPAR (/, / ) agonists 
Benzafibrate  
(9) 
    
Chiglitazar 
(10) 
None reported  None reported  Currently in Phase II  
Netoglitazone  None reported  None reported   
 
FUTURE PROSPECT ON DUAL/PAN PPAR MODU-
LATORS 
  Dual/pan PPAR modulators offer an efficient way of 
“killing two birds with one stone”, treating diabetes mellitus 
and preventing the complications/risk factors associated with 
it. The main problem with the development of dual/pan 
PPAR modulators is that the risks of the taking the drugs 
outweighs the benefit. In other to take advantage of the po-
tential use of PPAR modulators in the treatment of metabolic 
diseases, the dosage regimen and the medicinal chemistry of 
these PPAR ligands should be re-examined. 
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